200 related articles for article (PubMed ID: 38145461)
41. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
42. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
43. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
44. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
45. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.
Zhang Z; Li H; Deng Y; Schuck K; Raulefs S; Maeritz N; Yu Y; Hechler T; Pahl A; Fernández-Sáiz V; Wan Y; Wang G; Engleitner T; Öllinger R; Rad R; Reichert M; Diakopoulos KN; Weber V; Li J; Shen S; Zou X; Kleeff J; Mihaljevic A; Michalski CW; Algül H; Friess H; Kong B
Gastroenterology; 2021 Nov; 161(5):1601-1614.e23. PubMed ID: 34303658
[TBL] [Abstract][Full Text] [Related]
46. Oncogenic
Kim MP; Li X; Deng J; Zhang Y; Dai B; Allton KL; Hughes TG; Siangco C; Augustine JJ; Kang Y; McDaniel JM; Xiong S; Koay EJ; McAllister F; Bristow CA; Heffernan TP; Maitra A; Liu B; Barton MC; Wasylishen AR; Fleming JB; Lozano G
Cancer Discov; 2021 Aug; 11(8):2094-2111. PubMed ID: 33839689
[TBL] [Abstract][Full Text] [Related]
47. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
Kimura R; Ohtsuka T; Kubo M; Kajihara A; Fujii A; Watanabe Y; Mori Y; Ikenaga N; Nakata K; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2021 Apr; 51(4):619-626. PubMed ID: 32885350
[TBL] [Abstract][Full Text] [Related]
48. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
49. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
50. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression.
Hutchings D; Waters KM; Weiss MJ; Wolfgang CL; Makary MA; He J; Cameron JL; Wood LD; Hruban RH
Am J Surg Pathol; 2018 Nov; 42(11):1556-1561. PubMed ID: 30212393
[TBL] [Abstract][Full Text] [Related]
51. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
[TBL] [Abstract][Full Text] [Related]
52. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
[TBL] [Abstract][Full Text] [Related]
53. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
54. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
55. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.
Lee KE; Bar-Sagi D
Cancer Cell; 2010 Nov; 18(5):448-58. PubMed ID: 21075310
[TBL] [Abstract][Full Text] [Related]
56. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.
Ulanja MB; Moody AE; Beutler BD; Antwi-Amoabeng D; Rahman GA; Alese OB
Oncotarget; 2022; 13():828-841. PubMed ID: 35720978
[TBL] [Abstract][Full Text] [Related]
57. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
Gómez-Tomás Á; Pumarega J; Alguacil J; Amaral AFS; Malats N; Pallarès N; Gasull M; Porta M;
Environ Mol Mutagen; 2019 Oct; 60(8):693-703. PubMed ID: 31066938
[TBL] [Abstract][Full Text] [Related]
58. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
59. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
60. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
